Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics (NASDAQ:SAGE) on Tuesday, setting a price target of $77, which is approximately 2.48% below the present share price of $78.96.
Divan expects SAGE Therapeutics to post earnings per share (EPS) of $18.71 for the second quarter of 2021.
The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $103.14.
The analysts price targets range from a high of $189 to a low of $77.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.11 billion and a net profit of $973.85 million. The company's market cap is $4.61 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.1% and a 49.07% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.